[ slot 1 ]
Commercialization, reimagined.
We turn life sciences into , and .
Portrait, light background flowing into a dark shirt
The reality
Across Europe, turns innovation into , and .

Selected market indicators; figures vary by asset, therapeutic area and market. The “up to 80%” orphan drug figure is a widely cited industry estimate.

Innovation is not the problem. The gap between approval and access is.

What we are
LUMYNA sits at the intersection of , , and .

We don’t stop at strategy.

Portrait, dark background flowing into a light shirt
Our approach
We , we , we .

From insight to execution. From execution to impact.

Four capabilities
One integrated platform: , , and .

We don’t just launch products. We build markets.

Why LUMYNA
by default, in life sciences, by design, across capabilities and about partnerships.

Small by design. Senior by default.

The LUMYNA model
One partner, four ways to engage: , , , .

That is the difference between advising on commercialization and actually being a commercialization partner.

Rare disease
Where and patient need meet most sharply, we build for a narrow .

Because rare should never mean unreachable.

Europe
One continent, thirty commercial realities, where becomes .

One vision. Local intelligence. Connected execution.

Who we work with
We work with , and .

We don’t just assess the market. We understand what it takes to win in it.

The LUMYNA ecosystem
One platform, five capabilities: , , , and .
Our philosophy
Less complexity. More clarity. Better execution.

Clarity creates confidence. Confidence creates action. Action creates impact.

About LUMYNA
Built by operators, our spans the work and our is where value is created.
Insights
Perspectives on , the European , and hidden .
Innovation deserves patients.

But getting there requires more than science. It requires clarity. It requires access. It requires execution. It requires the right partner.

From science to market. From market to patients.

Commercialization, reimagined.

Advisory · Access · Commercialization · Growth

Zurich · Switzerland

Contact · LinkedIn · Privacy · Legal

© 2026 LUMYNA Pharma